Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 4/2017

01-08-2017 | Original Article

Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer

Authors: Mao Lin, Shu-Zhen Liang, Xiao-Hua Wang, Ying-Qing Liang, Ming-Jie Zhang, Li-Zhi Niu, Ji-Bing Chen, Hai-Bo Li, Ke-Cheng Xu

Published in: Immunologic Research | Issue 4/2017

Login to get access

Abstract

In this study, the safety and clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) were evaluated. From July 2016 to March 2017, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n = 30) and (2) the cryoablation combined with allogenic NK cell group (n = 30). The changes in immune function, quality of life, and clinical response were evaluated. We found that allogenic NK cells combined with cryosurgical treatment for advanced NSCLC have a synergistic effect, which not only enhancing the immune function of patients, improving the quality of life, and significantly increasing the response rate (RR) and disease control rate (DCR) compared to cryoablation group. This study is the first clinical trial of allogenic NK cells combined with cryosurgery for the treatment of advanced NSCLC and preliminaily its safety and efficacy.
Literature
1.
2.
Chen Z, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.CrossRefPubMed
3.
Yang L, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013;62:65–73.CrossRefPubMed
4.
Zhao M, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014;7:1403–7.PubMedPubMedCentral
5.
Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer--the smoke clears. N Engl J Med. 2005;352:2640–2.CrossRefPubMed
6.
Keller SM, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern cooperative oncology group. N Engl J Med. 2000;343:1217–22.CrossRefPubMed
7.
Felip E, et al. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol. 2013;25:115–20.CrossRefPubMed
8.
Sharma A, et al. How I do it: radiofrequency ablation and cryoablation of lung tumors. J Thorac Imaging. 2011;26:162–74.CrossRefPubMed
9.
Maiwand MO, et al. The application of cryosurgery in the treatment of lung cancer. Cryobiology. 2004;48:55–61.CrossRefPubMed
10.
Kornprat P, et al. Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg. 2007;142:1087–92.CrossRefPubMed
11.
Levy D, et al. Current state of urological cryosurgery: prostate and kidney. BJU Int. 2010;105:590–600.CrossRefPubMed
12.
Izumi Y, et al. The acute effects of transthoracic cryoablation on normal lung evaluated in a porcine model. Ann Thorac Surg. 2005;79:318–22. discussion 22CrossRefPubMed
13.
14.
Xu KC, et al. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol. 2003;9:2686–9.CrossRefPubMedPubMedCentral
15.
Orlacchio A, et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol. 2008;31:587–94.CrossRefPubMed
16.
Aerts JG, et al. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res. 2013;73:2381–8.CrossRefPubMed
17.
Lv M, et al. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther. 2014;13:3152–62.CrossRefPubMed
18.
19.
Thomas A, et al. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13:e301–10.CrossRefPubMed
20.
Hasegawa T, et al. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol. 2014;2:685–94.PubMedPubMedCentral
21.
22.
23.
Zhao Y, et al. Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-beta signaling pathway. Onco Targets Ther. 2015;8:1553–9.PubMedPubMedCentral
24.
25.
Wang D, et al. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014;14:251.CrossRefPubMedPubMedCentral
26.
Li JJ, et al. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012;35:189–95.CrossRefPubMed
27.
Pan K, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res. 2014;20:3003–11.CrossRefPubMed
28.
Pan K, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305–11.CrossRefPubMed
29.
Ljunggren HG, et al. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7:329–39.CrossRefPubMed
30.
31.
Niu L, et al. Combination of cryosurgery and iodine-125 seeds brachytherapy for lung cancer. J Thorac Dis. 2012;4:504–7.PubMedPubMedCentral
32.
33.
Witt CS, et al. The relevance of natural killer cell human leucocyte antigen epitopes and killer cell immunoglobulin-like receptors in bone marrow transplantation. Vox Sang. 2006;90:10–20.CrossRefPubMed
34.
Forte P, et al. HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells. Xenotransplantation. 2009;16:19–26.CrossRefPubMed
35.
Kunert K, et al. KIR/HLA ligand incompatibility in kidney transplantation. Transplantation. 2007;84:1527–33.CrossRefPubMed
36.
37.
Imai C, et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106:376–83.CrossRefPubMedPubMedCentral
38.
39.
Goldberg SN, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005;16:765–78.CrossRefPubMed
40.
Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
41.
42.
Asimakopoulos G, et al. Cryosurgery for malignant endobronchial tumors: analysis of outcome. Chest. 2005;127:2007–14.CrossRefPubMed
43.
Yamauchi Y, et al. Percutaneous cryoablation for pulmonary nodules in the residual lung after pneumonectomy: report of two cases. Chest. 2011;140:1633–7.CrossRefPubMed
44.
Ljunggren HG, et al. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today. 1990;11:237–44.CrossRefPubMed
45.
Mikelsaar AV, et al. Epitope of titin A-band-specific monoclonal antibody Tit1 5 H1.1 is highly conserved in several Fn3 domains of the titin molecule. Centriole staining in human, mouse and zebrafish cells. Cell Div. 2012;7:21.CrossRefPubMedPubMedCentral
46.
Burns LJ, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32:177–86.CrossRefPubMed
47.
de Magalhaes-Silverman M, et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother. 2000;23:154–60.CrossRef
48.
Iliopoulou EG, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781–9.CrossRefPubMed
49.
Re F, et al. Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer. 2006;107:640–8.CrossRefPubMed
50.
Geller MA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13:98–107.CrossRefPubMed
Metadata
Title
Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer
Authors
Mao Lin
Shu-Zhen Liang
Xiao-Hua Wang
Ying-Qing Liang
Ming-Jie Zhang
Li-Zhi Niu
Ji-Bing Chen
Hai-Bo Li
Ke-Cheng Xu
Publication date
01-08-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 4/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-017-8927-x

Other articles of this Issue 4/2017

Immunologic Research 4/2017 Go to the issue

Original Article

Estrogen receptor alpha gene (ESR1) polymorphism and its interaction with smoking and drinking contribute to susceptibility of systemic lupus erythematosus

Review

Dendritic cell-based immunotherapy: a basic review and recent advances

Original Article

Vitamin D inhibits the Staphylococcal enterotoxin B-induced expression of tumor necrosis factor in microglial cells

Review

Resolution of inflammation pathways in preeclampsia—a narrative review

Original Article

Innate defense regulator IDR-1018 activates human mast cells through G protein-, phospholipase C-, MAPK- and NF-ĸB-sensitive pathways

Original Article

Thymus vulgaris L. and thymol assist murine macrophages (RAW 264.7) in the control of in vitro infections by Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans